Coping with Job Lock

 

When you're unable to take a new job because your new employer's insurer refuses to cover certain preexisting conditions, including cancer, that's called "job lock." It reduces your job mobility and may limit your income potential.

Many people once found themselves in that predicament if they, or someone in their family, was in cancer treatment. One study of Indiana workers who had health insurance through their employers found that chronic illness reduced their job mobility by about 40 percent.

Yet you may be more fearful about job lock than is warranted. In 1997, the federal Health Insurance Portability and Accountability Act (HIPAA) was passed. It limits the exclusions for preexisting conditions. As a result, if you are in a group health plan now and are moving to a job that has coverage with another group health plan, the new insurer cannot refuse you coverage because of cancer or other preexisting conditions. This often requires that you have little or no gap in coverage, such as being uninsured for 63 days or more.

Job lock protection under HIPAA covers group health plans in every U.S. state, but each state interprets the law differently. Some will allow a "group of one" category.

Plan carefully before switching jobs:

  • Contact your state's health insurance assistance program to make sure that you won't be left uncovered.
  • Ask your current employer for a "certificate of creditable coverage" to verify that the group plan is covered under HIPAA.
  • If you're leaving to become self-employed, you may have to meet special criteria to retain coverage.
  • Haven't decided what you want to do? Make sure you have COBRA, or some sort of continuation coverage, to keep your HIPAA protection against preexisting condition clauses.
This content was last reviewed August 15, 2010 by Dr. Reshma L. Mahtani.
Latest Cancer News
REFILE: Komen charity under microscope for funding, science

February 8, 2012 — NEW YORK (Reuters) - The Susan G. Komen for the Cure charity defines its mission as finding a cure for breast cancer. In recent years, however, it has cut by nearly half the proportion of fund-raising dollars it spends on grants to scientists working to understand the causes and develop effective new treatments for the disease.

US FDA panel votes against wider use of Amgen drug

February 8, 2012 — WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.

US consumers want tougher probe of engineered salmon

February 8, 2012 — WASHINGTON (Reuters) - Three U.S. consumer groups petitioned the Food and Drug Administration on Tuesday to subject a new genetically engineered salmon to a more rigorous review process than is now in place before the fish can be approved as safe to eat.

Select news items provided by Reuters Health